Breakthrough dementia drug which slows down Alzheimer's disease may soon be offered at  home, avoiding a hospital trip

Trending 6 months ago
  • Lecanemab is presently awaiting authorisation from NHS spending watchdogs
  • The twice-a-week injection attacks a toxic macromolecule successful nan encephalon called amyloid

By Ethan Ennals

Published: 17:00 EDT, 28 October 2023 | Updated: 17:23 EDT, 28 October 2023

A breakthrough Alzheimer’s supplier that is tin of slowing nan disease’s progression could perchance beryllium taken astatine location alternatively than hospital.

Lecanemab, which is awaiting nan greenish ray for NHS usage and has already been approved by American regulators, was initially planned to beryllium fixed arsenic a twice-a-month infusion successful hospital.

But caller data, published by nan drug’s developer Eisai, suggests lecanemab is conscionable arsenic effective astatine slowing Alzheimer’s erstwhile fixed arsenic a twice-a-week injection. Unlike an infusion, which tin return respective hours done an IV bag, nan jabs tin beryllium done wrong minutes and do not require a travel to hospital.

Lecanemab useful by attacking a toxic macromolecule successful nan encephalon called amyloid which is linked to dementia symptoms.

Lecanemab, which is awaiting nan greenish ray for NHS usage and has already been approved by American regulators, was initially planned to beryllium fixed arsenic a twice-a-month infusion successful hospital

Experts judge a self-administered twice-weekly injection is arsenic effective arsenic a twice-a-month infusion

Experts person antecedently said it whitethorn beryllium excessively costly for nan wellness work to approve. But a move to location injections would trim nan costs of nan £20,000-a-year curen – which requires regular infirmary scans – arsenic NHS unit would not request to administer nan drug.

However, hopes that nan location injection would little nan complaint of vulnerable broadside effects – including encephalon swelling and bleeding seen successful earlier studies – were dashed. In fact, nan caller study, involving 70 participants, showed that nan number of patients experiencing these complications accrued from 17 to 22 per cent.

While astir patients who acquisition these broadside effects do not go severely unwell, successful immoderate cases nan problems tin beryllium life-threatening. Three members of a 1,800-participant proceedings of nan lecanemab infusion died arsenic a consequence of broadside effects linked to nan drug.

Speaking to nan MoS past night, encephalon doctors expressed interest astir location jabs, saying they feared that allowing patients to return nan supplier without nan adjacent supervision of nurses aliases doctors could person superior consequences.

‘Doctors don’t person immoderate measurement of predicting which patients will person these life-threatening broadside effects,’ says Robert Howard, professor of aged property psychiatry astatine University College London’s Institute of Mental Health. ‘So nan thought of allowing patients to return nan supplier astatine location without nan supervision of a wellness master is worrying.

‘The supplier institution needs to transportation retired larger tests which beryllium it is safe arsenic an injection, earlier they rotation it retired successful this form.’


Copyright © PAPAREAD.COM 2024

HEALTH